Please login to the form below

Not currently logged in
Email:
Password:

Roche invests €200m in Munich biotech centre

Creates new jobs with expansion of German diagnostic production

Roche Cobas
Roche's Cobas 6000 analysis module

Roche is to construct a new production facility at its Penzberg biotechnology centre near Munich in Germany to keep up with demand for its diagnostics products.

The Swiss pharma company will spend CHF240m (more than €200m) to construct the facility, creating 50 new jobs in the process.

Roche said it had seen “sustained global demand” for the reagents used in immunoassays, which enable doctors to detect biomarkers in patients' blood.

Roland Diggelmann, chief operating officer of Roche's Diagnostics Division, said: 'This investment in meeting global demand for immunoassays is further evidence of the success of our personalised healthcare strategy.

“Today's diagnostics make it possible to detect and differentiate the causes and triggers of chronic illnesses and acute conditions with greater precision than ever before.

“The new facility will ensure that we can continue to meet the rising demand for reagents.”

As the firm's largest biotech R&D site in Europe, Roche's Penzberg facility already employs nearly 5,000 people and the company's plans will see its production capacity for diagnostic test and control reagents increased.

Roche sells nearly 100 different tests for its Elecsys immunoassay platform and it is also the core technology in its Cobas system. 

The Cobas EGFR Mutation Test is currently under review by the FDA and is being used by Astellas to support its application to the US regulator for a new personalised licence for Tarceva.

13th December 2012

From: Research, Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...